Aspira Women’s Health Reports $676,000 Net Income in Q1 2026, Revenue Declines 14%

Aspira Women’s Health Inc. reported a net income of $676,000 for the first quarter of 2026, a significant turnaround from a net loss of $1.85 million in the same period last year. The company’s total revenue for the quarter was $1.97 million, a decrease of 14% compared to $2.28 million in the first quarter of 2025. This decline in revenue was attributed to a 14% drop in the volume of OvaSuite tests performed, which fell from 5,679 to 4,896 tests. The average unit price for OvaSuite tests remained relatively stable, with a slight increase to $402 from $401 year-over-year.

Operating expenses decreased by 32% to $3.27 million, down from $4.80 million in the prior year. This reduction was primarily driven by lower sales and marketing expenses, which fell by 50% to $543,000, and a 45% decrease in general and administrative expenses, which totaled $1.51 million. Research and development expenses increased by 26% to $1.23 million, reflecting ongoing investments in clinical trials and product development. The gross profit margin for product revenue also declined, dropping from 68.5% to 54.4%, largely due to increased costs associated with phlebotomy and personnel.

In terms of strategic developments, Aspira has been focusing on expanding its product offerings and enhancing its operational capabilities. The company is in the process of building out a molecular laboratory to facilitate the development of its ENDOinform test for endometriosis, which is expected to broaden its market reach. Additionally, Aspira has entered into various financing agreements, including a $10 million equity purchase agreement with Lincoln Park Capital, which allows the company to raise funds through the sale of its common stock.

As of March 31, 2026, Aspira reported total assets of $5.09 million and total liabilities of $11.30 million, resulting in a stockholders’ deficit of $6.21 million. The company had cash and cash equivalents of $1.34 million, down from $1.76 million at the end of 2025. Aspira anticipates continued challenges in achieving profitability, with management indicating that it expects to incur net losses and negative cash flows for the remainder of 2026. The company plans to address its liquidity needs through potential capital raises, cost reductions, and strategic partnerships.

Looking ahead, Aspira aims to enhance its market presence by increasing the adoption of its existing products and expanding into new therapeutic areas. The company is also focused on securing reimbursement for its tests from third-party payers, which is critical for driving revenue growth. Despite the current financial challenges, Aspira remains committed to its mission of providing innovative diagnostic solutions for women's health.